Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of Pevonedistat (MLN4924, TAK924) in Combination With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma

NCT03479268 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT03479268
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03479268 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of Pevonedistat (MLN4924, TAK924) in Combination With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma
Lead sponsor
City of Hope Medical Center
Phase
Phase 1
Overall status
Active, not recruiting
Start date
April 27, 2018
Completion date
November 5, 2026
Enrollment
18 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell prolymphocytic leukemia, recurrent chronic lymphocytic leukemia, recurrent diffuse large b-cell lymphoma, recurrent follicular lymphoma, recurrent lymphoplasmacytic lymphoma, recurrent mantle cell lymphoma, recurrent marginal zone lymphoma, recurrent non-hodgkin lymphoma, recurrent small lymphocytic lymphoma, refractory chronic lymphocytic leukemia, refractory diffuse large b-cell lymphoma, refractory follicular lymphoma, refractory lymphoplasmacytic lymphoma, refractory mantle cell lymphoma, refractory marginal zone lymphoma, refractory non-hodgkin lymphoma, refractory small lymphocytic lymphoma, richter syndrome